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Abstract  Fifty  years  after  the  ﬁrst  reports  of  Epstein-Barr  virus  (EBV)-associated  endemic
Burkitt’s lymphoma,  EBV  has  emerged  as  the  third  most  prevalent  oncogenic  virus  world-
wide. EBV  infection  is  associated  with  various  malignancies  including  Hodgkin  and  non-Hodgkin
lymphoma,  NK/T-cell  lymphoma  and  nasopharyngeal  carcinoma.  Despite  the  highly  speciﬁc
immunologic  control  in  the  immunocompetent  host,  EBV  can  cause  severe  complications  in  the
immunocompromised  host  (namely,  post-transplant  lymphoproliferative  disease).  This  is  partic-
ularly a  problem  in  patients  with  delayed  immune  reconstitution  post-hematopoietic  stem  cell
transplant or  solid  organ  transplant.  Despite  advances  in  diagnostic  techniques  and  treatment
algorithms  allowing  earlier  identiﬁcation  and  treatment  of  patients  at  highest  risk,  mortality
rates remain  as  high  as  90%  if  not  treated  early.  The  cornerstones  of  treatment  include  reduc-
tion in  immunosuppression  and  in  vivo  B  cell  depletion  with  an  anti-CD20  monoclonal  antibody.
However,  these  treatment  modalities  are  not  always  feasible  due  to  graft  rejection,  emer-
gence of  graft  vs.  host  disease,  and  toxicity.  Newer  treatment  modalities  include  the  use  of
adoptive T  cell  therapy,  which  has  shown  promising  results  in  various  EBV-related  malignancies.
In this  article  we  will  review  recent  advances  in  risk  factors,  diagnosis  and  management  of  EBV-
associated  malignancies,  particularly  post-transplant  lymphoproliferative  disease.  We  will  also
discuss new  and  innovative  treatment  options  including  adoptive  T  cell  therapy  as  well  as  man-
agement of  special  situations  such  as  chronic  active  EBV  and  EBV-associated  hemophagocytic
lymphohistiocytosis.
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Avances  recientes  en  los  factores  de  riesgo,  diagnóstico  y  tratamiento  de  la
enfermedad  linfoproliferativa  post  trasplante  con  infección  por  virus  de  Epstein-Barr
Resumen  A  cincuenta  an˜os  de  los  primeros  reportes  de  asociación  del  linfoma  de  Burkitt  con
el virus  de  Epstein-Barr  (VEB),  el  VEB  ha  emergido  como  el  tercer  virus  de  tipo  oncogénico
con mayor  prevalencia  a  escala  mundial.  La  infección  por  VEB  se  asocia  con  diversas  neo-
plasias,  incluyendo  el  linfoma  de  Hodgkin  y  el  no  Hodgkin,  linfoma  de  células  T/NK  y  carcinoma
nasofaríngeo.  A  pesar  del  control  inmunológico  altamente  especíﬁco  en  el  huésped  inmunocom-
petente,  el  VEB  puede  ocasionar  complicaciones  severas  en  el  huésped  inmunocomprometido
(es decir,  la  enfermedad  linfoproliferativa  post-trasplante).  Esto  es  un  problema  particular-
mente en  pacientes  en  quienes  se  retrasa  la  reconstitución  de  la  inmunidad  después  de  un
trasplante  de  células  madre  hematopoyéticas  o  un  trasplante  de  órganos  sólidos.  A  pesar  de  los
avances en  las  técnicas  de  diagnóstico  y  los  algoritmos  de  tratamiento  que  permiten  la  identiﬁ-
cación temprana  y  el  tratamiento  de  pacientes  de  alto  riesgo,  las  tasas  mortalidad  siguen  siendo
muy altas  (del  90%)  si  no  se  recibe  tratamiento  temprano.  La  piedra  angular  del  tratamiento
incluye  la  disminución  de  la  inmunosupresión  y  la  depleción  de  células  B  in  vivo  con  un  antic-
uerpo monoclonal  anti-CD20.  Sin  embargo,  estas  modalidades  de  tratamiento  no  son  siempre
posibles debido  al  rechazo  del  injerto,  la  enfermedad  de  injerto  contra  huésped  y la  toxicidad.
Nuevas modalidades  de  tratamiento  incluyen  el  uso  de  la  terapia  adoptiva  de  células  T,  que
ha mostrado  resultados  promisorios  en  diversas  neoplasias  relacionadas  con  el  VEB.  En  este
artículo se  revisan  los  avances  más  recientes  en  cuanto  a  los  factores  de  riesgo,  diagnóstico  y
tratamiento  de  las  neoplasias  asociadas  con  VEB,  particularmente  la  enfermedad  linfoprolifer-
ativa post-trasplante.  También  se  discuten  los  tratamientos  más  recientes  e  innovadores,  que
incluyen la  terapia  adoptiva  de  células  T  así  como  el  manejo  de  situaciones  especiales,  como
la infección  crónica  activa  de  VEB  y  la  linfohistiocitosis  hemafagocítica  asociada  con  VEB.
© 2015  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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negative.7,8 EBV-negative  PTLD  tends  to  occur  later  in  life. Introduction
pstein  Barr  Virus  (EBV)  is  a  highly  immunogenic  -herpes
irus  with  a  >90%  worldwide  seroconversion  rate  by  young
dulthood.1,2 Whereas  infections  in  childhood  are  usually
symptomatic,  in  adolescence  and  early  adulthood,  EBV
nfection  can  manifest  as  acute  mononucleosis,  a  typi-
ally  self-limiting  infection.  During  a  primary  infection,  the
ormal  host  mounts  a  vigorous  cellular  immune  response
onsisting  of  both  CD4+  and  CD8+  cytotoxic  T  lympho-
ytes  (CTLs).  These  CTLs  effectively  control  both  primary
BV  infection  and  periodic  reactivations  by  targeting  both
ytic  and  latent  cycle  antigens.3 Despite  the  highly  speciﬁc
mmunologic  control  in  the  immunocompetent  host,  EBV
an  cause  severe  complications  in  the  immunocompromised
ost,  particularly  patients  with  delayed  immune  reconstitu-
ion  post-hematopoietic  stem  cell  transplant  (HSCT)  or  solid
rgan  transplant  (SOT).  In  addition  to  being  the  primary
irus  associated  with  post-transplant  lymphoproliferative
isease  (PTLD),  endemic  Burkitt’s  lymphoma,  and  up  to
0%  of  Hodgkin  (HL)  and  non-Hodgkin  lymphoma  (NHL),
ncontrolled  EBV  infection  is  the  cause  of  many  HIV-  or
IDS-associated  lymphomas.1,4 Whereas  the  causative  rela-
ionship  between  EBV  and  the  aforementioned  disorders  is
ell  established,  more  recently  EBV  viremia  has  been  linked
o  hemophagocytic  lymphohistiocytosis  (HLH)  with  associ-
ted  chronic  active  EBV  infection  (CAEBV).5 The  common
enominator  in  all  of  these  scenarios  appears  to  be  the
a
a
Pack  of  EBV-speciﬁc  T  cells  able  to  successfully  control  the
nfection.  Whether  this  is  due  to  pre-transplant  conditioning
egimens,  the  prolonged  immunosuppression  necessary  fol-
owing  transplant,  or  anergic  T  cells  incapable  of  recognizing
nd  controlling  EBV  infection,  all  of  these  patients  possess
he  perfect  immunosuppressed  environment  for  unchecked
BV  reactivation  and  its  sequelae.6
In  this  article  we  will  review  recent  advances  in  risk
actors,  diagnosis  and  management  of  EBV-associated  malig-
ancies,  particularly  PTLD.  We  will  also  discuss  new  and
nnovative  treatment  options  including  adoptive  T  cell  ther-
py  as  well  as  management  of  special  situations  such  as
AEBV  and  EBV-associated  HLH.
. Post-transplant lymphoproliferative
isease: pathogenesis and risk factors
TLD  is  a  heterogeneous  group  of  malignant  diseases  ran-
ing  from  the  classic  polyclonal  subtype  to  more  aggressive,
onoclonal  forms.  Nearly  85%  of  cases  are  of  B-cell  lin-
age,  with  the  remaining  15%  of  cases  of  T  or  NK  cell
ineage.  The  majority  of  PTLD  cases  are  associated  with
BV  infection,  whereas  only  ∼30%  of  reported  cases  are  EBVnd  be  monomorphic  in  origin  (T-  or  NK-cell  neoplasms),
lthough  the  etiology  of  the  vast  majority  of  EBV-negative
TLD  remains  unknown.9
33
Table  1  Type  of  transplant  and  risk  of  PTLD.
Transplant  PTLD
1  year  5  year
Lung  3.1%  9.2%
Liver 1.8%  3.8%
Heart 1.3%  4.3%
Kidney 1.2%  2.0%
Intestinal  5.1%  9.4%
Note: Cumulative 1 year and 5 year incidence of post-transplant
lymphoproliferative disease (PTLD) in pediatric SOT recipients
stratiﬁed by organ as reported in the 2012 OPTN/SRTR Annual
Report (*Data reported combined for adults and pediatric recipi-
s
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3Risk  factors,  diagnosis  and  management  of  EBV  PTLD  
Patients  are  at  highest  risk  for  developing  PTLD  within
the  ﬁrst  year  following  transplant,  with  >  80%  of  cases  occur-
ring  within  this  time  frame.10,11 Several  characteristics
make  post-HSCT  recipients  more  susceptible  to  PTLD.  Estab-
lished  risk  factors  include  transplantation  from  an  unrelated
or  mismatched  donor  (including  haploidentical  or  cord
blood),  donor-recipient  serological  mismatch  in  relation  to
EBV,  graft  T-cell  depletion,  use  of  antithymocyte  globulin
(ATG)  and  prolonged/intense  immunosuppression  for  pre-
vention/treatment  of  graft  vs.  host  disease  (GVHD).10--14
Other  studies  have  also  identiﬁed  use  of  reduced  condition-
ing  regimens  and  acute  GVHD  ≥grade  2  as  risk  factors.6,15
Although  the  incidence  of  PTLD  after  HSCT  varies  in  the  lit-
erature,  it  can  increase  from  ∼2%  up  to  10--20%  in  patients
with  the  aforementioned  risk  factors.6,10,11,15
In  contrast  to  the  post-HSCT  setting,  the  overall  inci-
dence  of  PTLD  post-SOT  has  declined  likely  due  to  enhanced
post-transplant  quantitative  monitoring  of  EBV  viral  load
and  subsequent  adjustment  of  immunosuppression  when
indicated.  Recent  data  from  the  Organ  Procurement  and
Transplant  Network  (OPTN)  reports  a  5-year  cumulative
incidence  of  PTLD  in  pediatric  SOT  recipients  of  2-9%.
The  highest  incidence  of  PTLD  is  typically  seen  in  lung
and  intestinal  transplant  recipients,  with  historical  single
center  studies  reporting  an  incidence  in  intestinal  trans-
plant  recipients  as  high  as  30%  (Table  1).16 This  is  a
reﬂection  of  immunosuppression  intensity  as  well  as  the
transmission  of  lymphoid  tissue  in  the  allograft  (a  poten-
tial  source  for  primary  EBV  infection).  Age  of  the  transplant
recipient  and  EBV  donor/recipient  mismatch  are  additional
major  risk  factors.  A  large  longitudinal  study  of  >  3000  pedi-
atric  heart  transplant  recipients  found  that  25%  of  EBV
I
a
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Table  2  PTLD  treatment  and  clinical  outcomes.
Patient  characteristics Clinical  features
39  pediatric  SOT  PTLD  
55 SOT  PTLD  
133 high-risk  post-allo-HSCT Pre-emptive  (high  EBV  load)
threshold  1000  copies/mL
PTLD (N  =  13)  
64 post  allo-HSCT  Pre-emptive  (high  EBV  load)
Threshold  500  copies/mL
Ongoing elevated  levels  x  4  
144 allo-HSCT  (pediatrics  +  adults)  PTLD  
21 active  disease  Refractory  lymphoma  
29 ﬁrst  or  later  remission  Lymphoma  at  high  risk  for
relapse
Cy, cyclophosphamide; Pred, prednisone; RI, reduction of immunosupp
free survival; PD, progressive disease; ER, effective rate (*only those wents. Adapted from 2012 Annual report of US Organ Procurement
and Transplantation) (Ref. 19).
eronegative  recipients  (aged  4-7  years)  receiving  organs
rom  EBV+  donors  developed  some  form  of  PTLD.17 The  use  of
ymphocyte-depleting  agents  and  elevated  tacrolimus  lev-
ls  has  similarly  been  implicated  in  the  development  of
TLD.18,19
Although  the  incidence  of  EBV-associated  PTLD  has  not
hanged  in  recent  years,  the  mortality  rate  can  be  as  high
s  90%  if  not  treated  early.20 Table  2
.  Clinical presentationn  an  immunocompetent  host,  primary  EBV  infection  is  either
symptomatic  or  associated  with  fever,  fatigue  and  lym-
hadenopathy.  This  initial  infection  is  typically  followed  by
Treatment  Outcomes  Ref.
Cy/Pred
chemotherapy
CR  =  82%
OS  =  86%
Graft  survival  =  90%
26
Cy/Pred
chemotherapy  +
rituximab
CR  =  37%
2y  EFS  =  71%
27
Rituximab  (10/12)  22  patients  with  EBV
reactivation
CR  =  83%
PD  =  17%
28
Rituximab  (13/13)  PTLD  related
mortality  =  69%
Antiviral  only  or
RI  +  anti-viral  therapy
ER  =  24/64  (37.5%)* 20
Rituximab  ER  =  14/15  (93.3%)*
Rituximab
Rituximab  +  RI
OS  =  100/144  (69.4%)
OS  =  43/51  (84%)
15
EBV-CTL  CR  =  57.1%;  PR  =  4.8% 32
EBV-CTL  EFS  =  50%
CR  =  27/29  (93.3%)
EFS  =  82%
ression; CR, complete response; OS, overall survival; EFS, event-
ho achieved complete remission of PTLD survived); Pts, patients.
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n  EBV-speciﬁc  CTL-mediated  response,  leading  to  tightly
ontrolled  regulation  of  viral  reactivation.3
In  contrast,  primary  EBV  infection  or  reactivation  in  the
mmunocompromised  host  (particularly  those  post-HSCT  or
OT)  may  present  as  a  life-threatening  disease  characterized
y  fever,  lymphadenopathy,  mononucleosis-like  syndrome,
entral  nervous  system  (CNS)  disease/myelitis,  pneumonia,
epsis-like  syndrome  and  PTLD  (typically  associated  with  EBV
iremia  as  measured  by  PCR).14,20 Additionally,  in  SOT  recip-
ents,  PTLD  may  present  as  allograft  failure  without  other
ymptoms.21
. Diagnosis and importance of frequent
creening in at-risk patients
ne  of  the  most  challenging  management  questions  to
nswer  in  patients  with  EBV-related  malignancies  is  when
o  initiate  treatment.  In  the  case  of  rapidly  progressive
onoclonal  variants  such  as  diffuse  large  B-cell  lymphoma
DLBCL)/Burkitt’s  or  NK-T  lymphoma,  this  question  is  less
elevant  as  the  clinical  picture  typically  dictates  immediate
reatment.  However,  in  patients  with  EBV-PTLD  (whether
fter  HSCT  or  SOT),  the  answer  is  less  clear,  making  the
mportance  of  accurate  and  frequent  screening  techniques
itally  important.  Most  institutions  have  the  ability  to  mea-
ure  EBV  DNA  level  by  quantitative  methods.  Even  though
he  threshold  beyond  which  EBV  ‘‘DNA-emia’’  is  associated
ith  disease  varies  in  the  literature  (with  several  groups
uggesting  a  threshold  of  >  4000  copies/g,14 the  European
onference  in  Infections  in  Leukemia  (ECIL  4th) recommends
eekly  quantitative  monitoring  of  EBV  DNA  in  high-risk
atients  for  at  least  3  months  following  transplant.  However,
nly  50%  of  post-HSCT  patients  with  an  EBV  DNA  level  >  4000
opies/g  subsequently  develop  PTLD.13,22 To  this  end,  algo-
ithms  have  been  developed  that  take  into  account  both
BV  DNA  load  and  additional  risk  factors  to  identify  high-risk
atients  in  whom  the  beneﬁt  of  early  therapy  may  outweigh
he  risks  involved.  In  fact,  Liu  et  al.  developed  a  moni-
oring  and  preemptive  therapy  approach  for  EBV  viremia
ased  on  duration  and  trend  in  viral  load.20 Of  interest,  in
ddition  to  viral  load  and  established  risk  factors  predict-
ng  progression  of  EBV  viremia  to  full-blown  PTLD,  the  time
rom  EBV  DNA-emia  to  EBV-associated  disease  was  very  short
range  0-17  days,  median  7  days).  In  our  experience,  the
ate  of  rise  and  clinical  symptomatology  may  indicate  even
ore  frequent  monitoring  is  necessary.  Therefore,  despite
he  ECIL  recommendation  for  weekly  monitoring  of  EBV
oad  in  high-risk  patients,  more  frequent  monitoring  may
e  necessary  to  allow  preemptive  therapy  of  patients  at
arlier  stages.20 This  strategy  has  proved  valuable  in  the
ost-SOT  setting  as  well.  In  a  recent  large  survey  of  71
OT  centers  in  Europe,  >  80%  reported  utilizing  EBV  DNA-
mia  monitoring  as  a  means  of  dictating  when  to  initiate
eduction  in  immunosuppression.  Over  half  of  the  centers
ueried  utilized  reduction  of  immunosuppression  or  a switch
o  mammalian  target  of  rapamycin  (mTOR)  inhibitors  as  a
herapeutic  strategy23.  Despite  the  frequency  of  these  prac-
ices,  evidence  is  lacking  with  regard  to  thresholds  of  EBV
NA-emia  at  which  immunosuppression  should  be  adjusted.
urthermore,  inter-laboratory  variation  in  assays  for  mon-
toring  of  EBV  DNA-emia  make  a  standardized  approach
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hallenging.  Despite  these  drawbacks,  the  importance  of
onitoring  the  rate  of  EBV  load  rise  is  key  to  effective
dentiﬁcation  of  patients  at  highest  risk,  regardless  of  the
ethod.
. Treatment
espite  identiﬁcation  of  patients  at  increased  risk  for
BV  viremia  leading  to  lymphoproliferative  disease,  deter-
ination  of  how  to  initiate  preemptive  therapy  remains
hallenging.14 Although  reduction  of  immunosuppression
lone  is  an  effective  way  to  re-constitute  EBV-speciﬁc  cel-
ular  immunity  and  treat  PTLD  (with  reported  efﬁcacy  rates
p  to  50%  in  some  studies),22,24 particularly  in  the  case  of
OT,  it  carries  the  risk  of  allograft  rejection,  with  up  to
alf  of  post-heart  transplant  patients  with  PTLD  treated  with
mmunosuppression  withdrawal  developing  acute  or  chronic
ejection  within  6 months25.  When  reduction  of  immuno-
uppression  (RI)  is  not  possible,  other  options  include
)  targeting  pathogenic  B  cells  using  a  monoclonal  antibody
Anti-CD20  such  as  rituximab,  which  can  yield  up  to  69%
verall  response  rates),15 sometimes  in  combination  with
ther  cytotoxic  chemotherapy,  and  ii)  restoration  of  the
mmune  response  to  EBV  using  adoptive  immunotherapy.  For
 ﬂow  chart  of  the  clinical  management  of  post-transplant
BV  reactivation/PTLD  see  Figure  1.
Although  there  is  no  consensus  regarding  the  optimal
anagement  of  PTLD,  several  large  studies  have  demon-
trated  that  the  addition  of  cytotoxic  chemotherapy  to  RI
/−  rituximab  can  be  beneﬁcial.  Most  chemotherapy  regi-
ens  utilized  for  EBV-PTLD  include  some  combination  of
yclophosphamide  (Cy),  prednisone  (Pred)  and  intermittent
oses  of  rituximab.  Gross  et  al.  reported  the  outcomes  of
9  pediatric  SOT  recipients  who,  after  failing  RI,  received
he  combination  of  Cy  (600  mg/m2) and  Pred  (2  mg/kg/day)
iven  every  3  weeks  x  6  cycles,  with  a  complete  response
CR)  rate  of  82%,  graft  survival  of  90%,  and  overall  survival
OS)  of  86%26.  In  a larger  Phase  II  trial  of  the  Children’s
ncology  Group,  55  patients  with  EBV+,  CD20  +  PTLD  post-
OT  (who  had  previously  undergone  a  trial  of  RI  for  at
east  1 week)  received  two  initial  cycles  of  Cy/Pred  (at
dentical  doses  as  the  previously  mentioned  study)  and  rit-
ximab  (375  mg/m2)  followed  by  four  additional  cycles  of
y/Pred.  Although  this  study  reported  a  lower  CR  rate  of
7%,  2-year  event  free  survival  (EFS)  was  71%,  indicat-
ng  the  potential  for  augmented  efﬁcacy  compared  to  RI
lone27.
.1.  B-cell  depletion  with  anti-CD20  monoclonal
ntibody
ven  though  improving  the  patient’s  immune  response  (by
educing  immunosuppression)  is  one  of  the  cornerstones  of
TLD  management,  it  may  not  be  the  best  option  for  patients
ith  active  GVHD.  Thus,  eliminating  B  lymphocytes  with  a
onoclonal  antibody  against  CD20  is  a  feasible  option.  Gar-
ia  et  al.  evaluated  the  response  to  preemptive  rituximab
n  133  high-risk  post-allo-HSCT  recipients  between  the  years
006  and  2013.  The  study  included  patients  receiving  vary-
ng  conditioning  regimens  [myeloablative,  reduced  intensity
r  total  body  irradiation  (TBI)  based],  with  similar  graft
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EBV DNA load monitoring
Clinical presentation 
Identification of risk factors
• Transplantation from an unrelated or
mismatched donor
• Donor-recipient EBV serology mismatch
• Use of anti-thymocyteglobulin (ATG) or
T cell depletion in vivo/ex vivo
• Cord blood HSCT
• Younger age of recipient
• Prolonged/intense immunosuppression
• Use of reduced conditioning regimens
• Acute GVHD ≥ grade 2
Early management based on risk factors Treatment
• If elevated EBV DNA load and
clinical symptoms are present, obtain
additional diagnostic tests/imaging
and proceed to treatment algorithm
Reduced immunosuppression and/or
alternative immunosuppressive agent:
• Weekly for high risk patients
• Threshold of > 4000 copies/µg is an
accepted cutoff to institute treatment
(although rate of rise  often more
important than actual number) 
• Duration of high EBV load 
• Mainly used in post-SOT setting
• 50% efficacy
• Increased risk of allograft rejection
• Not possible in the setting of GVHD
Recognition of symptoms
• Fever
• Lymphadenopathy
• Weight loss
• Mononucleosis-like syndrome
• CNS disease/myelitis
• Pneumonia
• Sepsis-like syndrome
• Allograft failure
Interpretation of clinical
presentation based on EBV DNA
load
• Rituximab (anti-CD20)*
• Cytotoxic chemotherapy
• DLI ( increased risk of GVHD
complications)
• Adoptive immunotherapy with
EBV-specific CTLs
For aggressive monoclonal PTLD
(Burkitt’sor DLBCL):
• Cytotoxic chemotherapy
(lymphoma regimen)
• HSCT (auto vs. allo)
• Adoptive immunotherapy
If progressive disease:
Figure  1  Flow  chart  of  the  clinical  management  of  post-transplant  EBV  reactivation/PTLD.  See  text  for  details.  *Rituximab  may
also be  recommended  before  clinical  manifestations  of  PTLD  as  pre-emptive  therapy.  HSCT,  hematopoietic  stem  cell  transplant;
SOT, solid  organ  transplant;  DLI,  unmanipulated  donor  lymphocyte  infusion;  GVHD,  graft  vs.  host  disease;  CNS,  central  nervous
system; CTL,  cytotoxic  T  lymphocyte;  PTLD,  post-transplant  lymphoproliferative  disease;  DLBCL,  diffuse  large  B-cell  lymphoma;
auto, autologous;  allo,  allogeneic.
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amanipulation  and  GVHD  prophylaxis  and  at  least  one  risk  fac-
tor:  HLA  disparity,  cord  blood  (CB)  transplant,  or  use  of  ATG
or  alemtuzumab  during  the  conditioning  regimen.  High-risk
patients  were  monitored  with  weekly  EBV  qPCR  from  time
of  HSCT.  Standard-risk  patients  were  monitored  weekly  fol-
lowing  the  addition  of  a  second  immunosuppressive  drug.
The  threshold  for  treatment  with  weekly  rituximab  at  a
dose  of  375  mg/m2 was  two  consecutive  viral  loads  of  >  1,000
copies/mL  or  a  single  load  of  >  2000  copies/mL.  Rituximab
was  given  until  viral  clearance,  and  then  patients  received
an  additional  dose  of  rituximab  after  the  virus  was  cleared.
If  there  was  suspicion  for  PTLD,  a  CT  scan  and  a  lymph  node
biopsy  were  obtained  and  if  PTLD  was  conﬁrmed  the  patient
received  two  doses  of  rituximab  following  viral  clearance.28
In  this  study,  16/22  patients  with  clinically  symptomatic  and
histologically  conﬁrmed  EBV-PTLD  (ten  of  whom  received  rit-
uximab)  achieved  CR  for  a  response  rate  of  83%.  Of  note,
these  patients  also  received  at  least  a  20%  dose  reduction  in
immunosuppression.28
Alternatively,  Liu  et  al.  created  a  preemptive  interven-
tion  protocol  based  on  duration  and  trend  in  EBV  viral  load.
After  detection  of  EBV  DNA-emia  in  two  consecutive  samples
(deﬁned  as  ≥500  copies/ml  in  plasma)  RI  (if  possible)  was
instituted,  as  well  as  initiation  of  antiviral  therapy  [such  as
ganciclovir  (10  mg/kg/day)  or  foscarnet  (100  mg/kg/day)].  If
ongoing  monitoring  showed  rising  titers  (elevated  on  at  least
four  occasions),  rituximab  was  begun.  Of  251  post-allo-HSCT
patients,  64  were  included  in  the  ﬁrst-phase  preemptive
t
O
r
wtudy,  with  24  (37%)  achieving  a  CR  [in  this  study,  CR  was
eﬁned  as  a  negative  EBV-DNA  load,  or  <  500  copies/ml  in
lasma  (which  was  the  threshold  for  the  assay  used),  and
he  absence  of  signs  and  symptoms  of  EBV-associated  dis-
ase]  and  40  with  no  response.  Twenty  ﬁve  of  the  patients
ho  did  not  respond  progressed  to  EBV-associated  disease
using  the  ECIL  deﬁnition  for  clinical  EBV  infection).  Of  the
5  patients  who  received  rituximab  14  (93.3%)  had  a  CR.
hese  ﬁndings  suggest  that  although  RI  plus  antiviral  agents
ay  be  a  reasonable  management  approach  for  low-risk
atients,  preemptive  rituximab  should  be  considered  for
igh-risk  patients.  It  is  worth  noting  that  although  antiviral
rugs  may  inhibit  virus  replication,  antivirals  alone  (with-
ut  combination  with  RI  or  rituximab)  have  not  been  shown
o  prevent  EBV-PTLD.  For  this  reason,  the  4th ECIL  does  not
ecommend  the  sole  use  of  antiviral  drugs  as  prevention  of
TLD.13,20
In  another  large  multicenter,  retrospective  analysis
f  4,466  allo-HSCT  recipients  at  19  European  Trans-
lantation  centers,  144  patients  were  diagnosed  with
TLD.  Patients  either  received  rituximab  (375  mg/m2 every
-10  days;  64%)  or  a  combination  of  rituximab  (375  mg/m2
very  6-10  days)  and  RI  (35%);  21%  of  the  patients  required
djuvant  chemotherapy  due  to  only  partial  response  (PR)
o  either  rituximab  alone  or  rituximab  with  additional  RI.
S  after  rituximab  alone  was  69.4%;  84%  of  patients  who
eceived  both  rituximab  and  RI  had  resolution  of  PTLD,
hereas  patients  who  did  not  have  RI  had  only  40%  OS.15
36  P.  Aguayo-Hiraldo  et  al.
Post HSCT or SOT
patient
HSCT donor,
patient (autologous)
or third party
Prepa ration  of  EBV CTL
by different methods
• LCL (8-12  wee ks)
• Nucleofection (2-3 weeks)
• Pepmi xes (10-14  days) 
Cells unde rgo sterilit y, phenotypic
and function al testin g, then  are
frozen for f uture use
EBV CTLs
Thawed cells and
admini stered to patient
with EBV PTLD
Isolate PBMCs
Figure  2  Schematic  diagram  of  adoptive  immunotherapy  with  cytotoxic  T  lymphocytes  (CTLs).  HSCT,  hematopoietic  stem  cell
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aransplant; auto,  autologous;  allo,  allogeneic;  PBMC,  peripheral
oid cell  lines;  SOT,  solid  organ  transplant;  PTLD,  post-transpla
Despite  the  effectiveness  of  these  therapies,  they  are
imited  by  toxicity  and  do  not  address  the  underlying  deﬁ-
iency  in  EBV-speciﬁc  T  cell  immunity.
.2.  Adoptive  immunotherapy
s  discussed  above,  the  immune  system  controls  EBV  infec-
ion  through  CD4  +  and  CD8  +  CTLs.  EBV  +  neoplastic  cells
xpress  immunogenic  antigens  that  are  potential  targets  for
TL-mediated  EBV-speciﬁc  cytotoxicity.  However,  in  the  set-
ing  of  signiﬁcant  immunosuppression  and  delayed  immune
econstitution  post-transplant,  this  control  is  inadequate.
Adoptive  immunotherapy  with  unmanipulated  donor  T
ells  and  EBV-CTLs  has  provided  well-tolerated,  effective,
nd  long-term  antiviral  protection.14 In  the  post-HSCT  set-
ing,  unmanipulated  donor  lymphocyte  infusions  (DLIs)  can
econstitute  EBV-speciﬁc  immunity  with  clinical  response
ates  from  60  to  90%.29 However,  GVHD  is  a  well-known
omplication  of  DLI.  Furthermore,  only  a  minority  of
atients  with  established  disease  achieves  sustained  CRs.30
 novel  and  increasingly  utilized  approach  to  the  treatment
f  EBV-PTLD  is  to  restore  the  impaired  immune  function
y  the  adoptive  transfer  of  EBV-speciﬁc  CTLs  (Figure  2).
n  fact,  when  compared  to  patients  receiving  unmanip-
lated  DLI,  patients  receiving  either  HLA  compatible  or
artially  HLA-matched  EBV-CTLs  had  similar  response  rates
73%  vs.  68%  respectively).31 Because  this  therapy  is  spe-
iﬁc  for  EBV-infected  cells,  risk  of  GVHD  is  minimal  (0%  vs.
7%  respectively  in  a  recent  study  by  Doubrovina  et  al.31).
ollard  et  al.  treated  50  patients  with  relapsed,  refractory
n=21)  or  high-risk  (due  to  history  of  multiply-relapsed  dis-
ase,  although  in  a  state  of  remission  at  time  of  treatment)
n  =  29)  EBV-associated  HL  or  NHL  with  autologous  EBV-CTLs.
t
c
m
pd  mononuclear  cells;  EBV,  Epstein-Barr  virus;  LCL,  lymphoblas-
phoproliferative  disease.
f  the  29  patients  at  high-risk  for  relapse  (where  CTLs  were
sed  as  adjuvant  therapy),  82%  had  EFS  following  EBV-CTL
nfusion,  whereas  11/21  patients  treated  with  active  dis-
ase  achieved  CR  as  well.  There  were  two  PRs,  with  one
atient  achieving  a  CR  after  an  additional  CTL  infusion.32
his  approach  has  been  employed  in  both  the  autologous
EBV-CTLs  generated  from  the  patient  themselves)  and  allo-
eneic  settings  (cells  generated  from  HSCT  donor  or,  as
iscussed  below,  healthy  third-party  donors).29
The  complexity  and  time  taken  to  generate  either  autol-
gous  or  allogeneic  EBV-CTLs  for  adoptive  transfer  has
een  a  limitation  to  widespread  clinical  applicability  (man-
facture  time  using  earlier  methods  can  take  up  to  12
eeks).  Therefore,  several  groups  have  successfully  short-
ned  the  manufacture  of  EBV-CTLs  by  eliminating  the  use  of
ymphoblastoid  cell  lines  (LCLs)  as  stimulating  antigen,  with-
ut  compromising  efﬁcacy.14 Generation  methods  include  i)
sing  nucleofection  to  transfer  DNA  plasmid  into  dendritic
ells  and  using  these  as  antigen  presenting  cells  (APCs),
 process  that  took  2-3  weeks,  and  reproducibly  created
BV-CTLs  speciﬁc  for  EBV  antigens  EBNA1,  BZLF1  and  LMP2
onﬁrmed  by  IFN- ELISpot  assay,29 ii)  IFN- capture,  in
hich  the  investigators  selectively  captured  and  infused
he  CTLs  secreting  the  most  IFN- in  response  to  antigen
timulation.33 Using  either  of  these  manufacture  techniques
ielded  promising  results,  with  8/10  patients  achieving  viro-
ogical  and  clinical  responses  in  the  study  by  Gerdemann
t  al.  although  only  three  responses  were  sustained.34,35
Members  of  our  group  have  successfully  optimized  an
ccelerated  manufacture  process  using  overlapping  pep-
ide  libraries  that  allows  production  of  virus-speciﬁc  T
ells  (VSTs)  in  as  little  as  10-14  days.  Peripheral  blood
ononuclear  cells  (PBMCs)  are  stimulated  with  overlapping
eptide  libraries  (pepmixes)  incorporating  the  antigens  of
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interest,  then  expanded  in  a  closed-system  for  10-14  days.
This  manufacture  method  has  been  quite  successful,  with
Papadopoulou  et  al.  generating  CTLs  speciﬁc  for  ﬁve  clini-
cally  problematic  viruses  in  the  post-HSCT  period  (including
EBV)  from  HSCT  donors;  94%  of  patients  treated  had  virologi-
cal  and  clinical  responses,  including  patients  with  EBV-PTLD
and  reactivation,  all  of  who  achieved  a  CR.36
Despite  the  success  of  adoptively  transferred  EBV-CTLs,
several  groups  have  reported  trends  associated  with  poor
clinical  response.31,32 For  one,  failure  of  the  EBV-CTLs  to
expand  in  vivo  is  associated  with  poor  response.  In  the  case
of  EBV-CTLs  generated  from  the  HSCT  donor,  treatment
failures  correlated  with  impaired  recognition  of  tumor
targets  by  the  infused  CTLs,  mainly  due  to  selective  HLA
restriction  by  alleles  not  shared  by  the  EBV-PTLD.  In  fact,
the  Memorial  Sloan  Kettering  (MSK)  group  saw  encouraging
clinical  responses  in  patients  who  had  previously  failed
donor-derived  CTLs  after  choosing  an  alternate  third-party
donor  with  conﬁrmed  EBV-CTL  activity  through  a  shared
HLA  allele.31
However,  despite  faster  manufacture  time,  the  lack  of
immediate  availability  of  EBV-CTLs  highlights  the  need  for  an
immediately  available  ‘‘off-the-shelf  product’’.36 This  strat-
egy  is  also  helpful  in  situations  where  there  is  not  a  readily
available  donor  to  generate  EBV-CTLs  from  cord  blood
(CB)/Matched  Unrelated  Donor  (MUD)  HSCT  or  post-SOT).
This  approach  has  been  an  active  source  of  investigation
in  several  centers  including  ours,  as  we  work  to  optimize
third-party  partially  matched  VST  banks  for  treatment  of
EBV-related  malignancies  and  other  viral  reactivations  as
well.  In  a  multicenter  study,  Leen  et  al.  created  a  bank
of  third-party  tri-virus  T  cells  (active  against  adenovirus,
cytomegalovirus  and  EBV)  generated  from  healthy  individ-
uals  with  common  HLA  types,  and  manufactured  using  the
LCL  generation  method.  Cells  were  frozen  and  stored,  thus
available  for  immediate  use.  Fifty  post-HSCT  patients  were
infused,  including  eight  with  rituximab-refractory  EBV-PTLD
and  one  with  persistent  EBV  DNA-emia,  with  a  6-week  CR
rate  of  66.7%.  Cells  persisted  up  to  12  weeks  post-infusion.
Of  note,  clinical  responses  were  noted  even  when  infused
CTLs  were  matched  at  only  a  single  HLA  allele,  with  no  major
GVHD  reported.37
Both  autologous  and  third-party  partially  HLA-matched
EBV-CTLs  have  been  used  in  SOT  recipients  as  well,  both
as  prevention  and  as  treatment  of  EBV-PTLD.  A  single  infu-
sion  of  autologous  EBV-CTLs  in  12  pediatric  heart  and  liver
transplant  recipients  at  high-risk  for  PTLD  prevented  devel-
opment  of  PTLD  at  1  year.38 In  a  study  of  over  30  SOT
recipients  with  PTLD  who  failed  conventional  therapy,  infu-
sion  of  third  party  partially  HLA-matched  EBV-CTLs  led  to  CR
or  PR  in  >  50%  of  patients  at  6  months.39
It  is  important  to  note  that  infusions  of  both  autologous
and  allogeneic  EBV-CTLs  have  been  well  tolerated.  Speciﬁ-
cally,  there  have  been  no  reported  infusion-related  adverse
events,  signiﬁcant  toxicity,  or  graft  rejection  attributable
to  CTL  infusion,  and  only  minimal  de  novo  GVHD.  Aside
from  one  report  from  our  center  of  systemic  inﬂamma-
tory  response  syndrome  (SIRS)  in  a  patient  with  bulky
refractory  EBV  lymphoma  approximately  2  weeks  after
receiving  EBV-speciﬁc  CTLs,  there  have  been  no  reports  of
cytokine  release  syndrome.  In  this  patient,  the  inﬂamma-
tory  response  was  concurrent  with  in  vivo  expansion  of  the
(
N
c37
TLs  and  characterized  by  fever,  tachycardia,  hypotension,
espiratory  distress,  and  elevated  inﬂammatory  markers.
ymptoms  resolved  with  steroids  and  etanercept.40
Although  adoptive  immunotherapy  with  EBV-CTLs  is  a
romising  approach,  optimization  of  this  therapy  is  depend-
nt  on  having  timely  universal  access  to  cellular  products,
ot  limited  to  specialized  centers.
.  Special cases
.1.  Chronic  active  EBV  infection  (CAEBV)  and
emophagocytic  lymphohistiocytosis  (HLH)  in  the
etting of  PTLD
t  is  appropriate  to  discuss  CAEBV  and  EBV-associated  HLH
ogether  as  the  entities  are  thought  to  exist  on  a  continuous
pectrum.  CAEBV,  which  can  occur  after  primary  EBV  infec-
ion,  can  be  of  B  or  T  cell  origin.  When  of  B  cell  origin,  the
resentation  and  management  is  similar  to  EBV-PTLD.  When
f  T  cell  origin,  it  is  similar  in  clinical  features  and  patho-
ogic  ﬁndings  to  EBV-associated  HLH,  although  EBV  +  HLH
ay  progress  to  a  monoclonal  T-cell  lymphoproliferative
isease.5,9,41
Whereas  PTLD  is  a  complication  of  decreased  CTL
mmune  surveillance  leading  to  increased  susceptibility  to
BV,  HLH  is  a  life-threatening  condition  resulting  from  exces-
ive  immune  activation,  deﬁned  by  the  occurrence  of  at
east  ﬁve  abnormalities:  fever,  splenomegaly,  cytopenias  in
t  least  two  hematopoietic  cell  lineages,  elevated  ferritin
nd  triglyceride  levels,  decreased  ﬁbrinogen  or  elevated
oluble  IL-2,  impaired  NK  cell  activity  and/or  hemophago-
ytosis  on  biopsy.  HLH  can  be  primary  or  secondary  and
an  occur  secondary  to  malignancy  or  treatment-related
mmunosuppression.42 Rarely,  HLH  occurs  after  HSCT  (inci-
ence  0.3%),  is  typically  triggered  by  EBV,  and  presents  with
lassic  features  of  HLH.  Several  case  reports  exist  detail-
ng  patients  transplanted  for  hematologic  malignancies  who
ubsequently  developed  EBV-related  HLH  and  PTLD  within
00  days  of  transplant.  Jha  et  al.  presented  a  case  of  a  2-
ear-old  who  underwent  liver  transplant  for  extra-hepatic
iliary  atresia,  presenting  9  months  after  transplant  with
evers,  hepatosplenomegaly,  pancytopenia,  EBV  viremia  of
34,000  copies/ml  and  bone  marrow  examination  consistent
ith  EBV-induced  HLH  treated  with  RI,  steroids  and  ritux-
mab  achieving  CR.  Reported  patients  have  been  treated
imilarly,  with  rituximab,  steroids,  and  reduction  or  discon-
inuation  of  immunosuppression,  with  symptomatic  recovery
fter  a  few  weeks  and  resolution  of  PTLD  within  months.
he  reported  patients  remain  in  sustained  remission  of  their
rimary  diseases43,44.
Although  anecdotal  considering  the  limited  numbers,  it
ppears  that  patients  who  present  with  concomitant  PTLD
nd  fulminant  HLH  post-HSCT  are  less  likely  to  respond  to
ithdrawal  of  immune  suppression  alone  and  will  require  at
east  the  addition  of  rituximab  or  steroids.
.2.  EBV-associated  nasopharyngeal  carcinoma
NPC)
PC  is  a  distinctive  histological  subtype  of  head  and  neck
ancer  which  is  rarely  seen  in  Western  countries,  but  highly
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translate  to  improved  outcomes.8  
ndemic  to  Southeast  Asia  and  Southern  China  (incidence
f  20-30/100,000)  accounting  for  up  to  20%  of  adult  can-
ers  in  this  region.45,46 Risk  factors  include  tobacco  and
xcessive  alcohol  intake.  Up  to  98%  of  NPC  cases  (par-
icularly  endemic)  are  EBV-positive.2 Treatment  for  early,
ocalized  disease  includes  radiotherapy  to  localized  areas  of
isease  and  involved  lymph  nodes,  with  local  control  rates
as  deﬁned  by  RECIST  (Response  Evaluation  Criteria  in  Solid
umors)  criteria]  of  80-90%.  In  contrast,  more  advanced  dis-
ase  has  suboptimal  response  to  radiotherapy  alone  (control
ate  of  30-65%).  However,  the  addition  of  platinum-based
hemotherapy  increased  control  rates  to  54-78%  in  reports
rom  the  National  Comprehensive  Cancer  Network  (NCCN)
nd  intergroup  trial  0099.47
Because  the  majority  of  NPC  cases  express  the  EBV  type
I  latency  pattern  (LMP-1,  LMP-2  and  EBNA),  NPC  is  an
deal  target  for  adoptive  T  cell  therapy.48--51 Several  groups,
ncluding  ours,  have  reported  promising  results  in  the  treat-
ent  of  advanced  NPC  using  EBV-speciﬁc  CTL  therapy.  Chia
t  al.  evaluated  the  safety  and  efﬁcacy  of  chemotherapy  in
ombination  with  LMP-2  speciﬁc  EBV-CTLs  in  a  Phase  II  clin-
cal  trial  including  38  patients.  After  a  median  follow  up  of
30  months,  2-  and  3-year  OS  rates  were  62.9%  and  37.1%,
espectively.  In  fact,  ﬁve  patients  who  received  CTLs  did
ot  require  additional  chemotherapy  for  >  34  months  follow-
ng  the  last  infusion.  Treatment  was  well-tolerated,  with  no
rade  3-5  toxicities,  with  the  most  common  adverse  effects
eing  grade  1-2  fatigue  and  myalgias,  transient  infusion-
ssociated  fever  and  grade  1  skin  rash.48
In  a  study  by  Comoli  et  al.,  ten  patients  with  progres-
ive  EBV+  stage  IV  NPC  who  had  failed  conventional  therapy
eceived  autologous  EBV-speciﬁc  CTLs.  Patients  received
etween  two  and  23  infusions,  with  two  patients  achieving
R,  four  patients  with  stable  disease  (lasting  4-15  months)
nd  four  with  progressive  disease.  In  three  of  the  patients
ho  had  clinical  beneﬁt  from  the  EBV-CTLs,  increased
requencies  of  LMP-2  speciﬁc  CTLs  were  detected  in  the
eripheral  blood,  a  phenomenon  that  has  been  noted  in
ther  studies  as  well.49 Louis  et  al.  also  evaluated  EBV-CTLs
n  a  Phase  I/II  Study  of  23  patients  with  NPC.  Seven  patients
ere  treated  in  the  dose  escalation  phase  of  the  study,  and
fter  no  dose-related  toxicity  occurred,  the  remaining  16
atients  were  treated  on  the  highest  tolerated  dose  level.
f  eight  patients  treated  in  remission,  ﬁve  remained  disease
ree  for  25-82  months.  Of  three  patients  treated  with  local
ecurrent  disease,  CR  was  achieved  in  two  patients  for  >  44
nd  >  53  months,  respectively.  Of  the  11  treated  patients
ith  metastatic  disease,  one  achieved  CR  and  one  patient
ad  CRu  (deﬁned  as  resolution  of  a  pre-infusion  imaging  ﬁnd-
ng  of  unknown  signiﬁcance).  The  remaining  patients  had
ither  PR  (n  =  1),  stable  disease  (n  =  2),  or  progressive  disease
n  =  6).50
.3.  Natural  killer/T-cell  lymphoma  (NK/T)
K/T  lymphomas  are  rare  lymphomas  that,  in  contrast  to  the
ajority  of  EBV-associated  malignancies,  typically  affecthe  immunocompetent  host.  Historically,  NK/T  lymphoma
as  a  very  poor  prognosis  with  5-year  survival  rate  of  <  50%
ith  conventional  chemotherapy  alone.1 However,  similar
o  EBV+  HL  and  NHL,  the  malignant  cells  in  NK/T  lymphoma
C
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xpress  a Type  II  latency  proﬁle  characterized  by  EBNA1
nd  LMP-2,  thus  making  it  a  potential  target  for  adoptive
 cell  therapy.  Bollard  et  al.  tested  this  approach  by  geneti-
ally  modifying  autologous  T  cells  to  increase  the  expression
nd  immunogenicity  of  LMP-2.  In  this  study,  9/10  patients
ith  high-risk  NKT  lymphoma  who  received  LMP-2  CTLs  in
 state  of  remission  remained  in  remission.  Strikingly,  5/6
atients  with  active  disease  had  overt  tumor  responses,
ith  sustained  CRs  (>9  months)  in  four  patients.52 In  a  more
ecent  study,  11  patients  with  extranodal  NK/T  lymphoma
reviously  treated  with  chemotherapy  received  autologous
MP-1/2A  CTLs  (two  cycles  of  four  weekly  doses,  1  month
part)  as  remission  consolidation.  The  infusions  were  well
olerated,  with  remarkable  OS  and  progression  free  survival
PFS)  of  100%  and  90%,  respectively.53
The  efﬁcacy  of  LMP-CTLs  as  treatment  of  NK/T  lymphoma
as  therefore  become  a  viable  option  for  a  disease  with
istorically  few  therapeutic  options.
. When a once indolent PTLD becomes an
ggressive  monoclonal lymphoma
nfortunately,  not  all  PTLD  is  responsive  to  conserva-
ive  withdrawal  of  immune  suppression,  institution  of  less
ggressive  cytotoxic  therapy,  and  adoptive  immunother-
py.  In  some  cases,  a  once  responsive  lymphoma  suddenly
ecomes  refractory,  corresponding  with  rising  levels  of  EBV
iral  load  and  clinical  symptomatology  (lymphadenopathy,
ever,  new  or  increased  lesions  on  CT  or  PET  scan).  When
edically  feasible,  repeat  biopsy  of  these  lesions  is  often
ecessary  to  determine  whether  a  polymorphic  PTLD  has
volved  into  a  more  monomorphic,  aggressive  lymphoma
uch  as  Burkitt’s  or  DLBCL.  If  biopsy  conﬁrms  a  more  aggres-
ive  subtype,  only  a  minority  of  patients  will  respond  to  RI
r  rituximab  alone  as  compared  to  their  polymorphic  coun-
erparts.  For  this  reason,  if  biopsy  conﬁrms  one  of  these
ore  aggressive  subtypes,  patients  will  beneﬁt  from  more
ggressive  chemotherapy-based  regimens  that  are  standard-
f-care  for  the  speciﬁc  type  of  lymphoma.  Because  these
ases  can  prove  refractory  to  chemotherapy  alone,  the
ecommendation  from  the  American  Society  for  Blood  and
arrow  Transplant  (ASBMT)54 is  to  refer  patients  who  fail
hemotherapy-based  regimens  for  autologous,  or  in  some
ases,  allogeneic  HSCT.55
Despite  the  development  of  early-intervention-based
reatment  guidelines,  long-term  survival  of  patients  with
TLD  and  other  EBV-related  malignancies  remains  subopti-
al.  Continued  improvements  in  both  risk  stratiﬁcation  and
dentiﬁcation  of  alternative  treatment  options  (speciﬁcally
BV-speciﬁc  CTLs)  are  essential  to  lessening  the  morbidity
nd  mortality  caused  by  EBV-associated  diseases.  The  con-
inued  optimization  of  autologous  EBV-CTLs  and  immediate
vailability  of  ‘‘off  the  shelf’’  EBV-CTLs  offers  the  possibil-
tyof  improved  access  to  this  therapy,  which  will  hopefullyonﬂict of interest
he  authors  declare  no  conﬂict  of  interest  of  any  nature.
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